Category

Biotech Stocks

stocks

3 Best Biotech Stocks to Buy (and 3 to Avoid)

By , Money Morning - • Print | Email

Biotech stocks find themselves in a very interesting, and potentially very profitable, situation right now.

It's widely believed by public health officials that we can't return to "normal" until scientists discover a coronavirus vaccine that can be widely distributed.

That's the primary reason why the Trump administration launched "Operation Warp Speed."

The U.S. government is investing billions of dollars in biotech companies to develop a COVID-19 vaccine as quickly as possible – so the world can return to normal.

But not all biotech stocks are worth buying right now.

Read more...

Biotechnology

This "Orphan Drug" Biotech Could Double in Less Than Three Years

By , Defense + Tech Specialist, Money Morning • @Robinson_STI - • Print | Email

The three biggest Big Pharma "blockbuster" medicines of all time target high cholesterol (Lipitor), inflammatory diseases (Humira), and digestive afflictions (Nexium) and have pulled in a combined $350 billion – and counting.

But what about people suffering from rare diseases like cystic fibrosis, pancreatic cancer, and so on?

Here in America, Washington understands the need for these "orphan drugs" targeting rare diseases, which is why the "Orphan Drug Act of 1983" offers a seven-year window of tax reductions and the exclusive right to market a drug for a particular rare disease.

To date, more than 600 orphan drugs have been approved by the FDA.

And the global market for orphan drugs targeting rare diseases is growing at double the rate of the non-orphan market.

But more needs to be done. And that "more" will create a massive investment portal – provided you pick the best-positioned companies.

That's why today, our Michael Robinson going to show you a revved-up leader in the specialty-drugs market whose shares could double in under three years...

Biotechnology

Read This Before You Play a Single One of the Biotechs Fighting COVID-19

By , Technical Trading Specialist, Money Morning • @DRBarton_Stocks - • Print | Email

Georgia, South Carolina, and Florida have announced that they are loosening quarantine restrictions; at least 13 more states have announced plans or "roadmaps" to do more or less the same thing.

There's an urgent desire to get "back to normal" as quickly as possible because the social and economic devastation – record unemployment, more than 55,300 deaths, massive lockdowns, shrinking GDP, and of course the virus itself – of the coronavirus pandemic has been so profound.

And this has all happened in a little more than a month. People are understandably anxious to put all this behind them, myself very much included.

But the stakes of "normalcy" are higher than we're being told. The successful reemergence of people into the world will require far more than just repeated reminders to wash your hands and not touch your face.

Social distancing and limited interaction can slow the spread; there's mounting evidence in the United States and other countries that we've done precisely that. But it's far from clear how much those actions could really prevent widespread illness as lockdowns ease and stay-at-home orders are lifted.

Because it's very likely that we won't be truly "safe" until a proven treatment and effective vaccine are available.

The more we learn about this virus, the more we're aware of why its ongoing impact, and the "right" way to reopen the economy, remain so uncertain.

Here's what we do know… Full Story

Here's what we do know... Full Story

Biotechnology

The 3 Best Biotech Stocks to Buy Offer 182% Upside on a Coronavirus Cure

By , Money Morning - • Print | Email

The Dow sank 600 points when news of coronavirus first began circulating.

Though it's regained some of those losses, the market may still hurt for a time.

However, there are a few biotech stocks charged with seeking out a vaccine that could pop over the next year.

In fact, our best biotech stock offers 182% upside potential.

Read more...

Stocks

Insiders Believe This Small-Cap Biotech Stock Could Jump 478%

By , Executive Producer, Money Morning - • Print | Email

If you're a seasoned investor or just starting out, you might have heard of insider buying when it comes to a stock.

Insider buying can predict success in a stock.

And today, I'm going to show you a stock that's getting bought up by insides – meaning it's poised for a breakout.

Six analysts gave this stock an average 478% growth target.

I'm not as bullish as those guys, but my 72% target is still good reason to pay attention to this stock.

Read more...

Stocks

The 3 Best Biotech Stocks to Buy in Q4 2019

By , Guest Writer, Money Morning - • Print | Email

Investors hate uncertainty. If the future of a business or industry is in question, stocks suffer.

That's certainly the case with the biotech sector right now. In 2019, biotech stocks have been pummeled. The Nasdaq Biotech Index is down almost 12% over the last six months.

What's holding back the group? Uncertainty about drug prices is a huge overhang for biotech stocks

But a lot of that uncertainty was just removed, meaning the best biotech stocks to buy in Q4 could skyrocket soon...

Stocks

This Deal Could Put You Up Much More Than 149%

By , Executive Editor, Money Morning - • Print | Email

It was the very first stock that I recommended on the very first day we published Private Briefing nearly eight years ago…

I've re-recommended the shares to my readers several times, and when something happened that I felt everyone should know about, we made sure to get the news out in Money Morning, too.

When I first wrote about it in 2011, shares were trading at $8.60. As of Wednesday morning, the stock was sitting near all-time highs at $171 – monumental gains of nearly 1,900%.

But I'm writing today because it's been a big winner for you, too – more than 149%.

And I don't think it's done, not by a long shot…

Let me tell you about the company - and all about this latest development...

Biotechnology

Biotech IPOs Are Getting the Headlines - Here's Where You'll Find the Profits

By , Guest Writer, Money Morning - • Print | Email

For many investors in 2019, the name of the game is speculation.

Of course, it has also been a huge year for initial public offerings. As always, IPOs and speculation often go hand in hand.

As we look ahead to the second half of 2019, IPOs will be one of the biggest focuses, and we expect the biotech IPOs to take center stage.

Read more...